Clinical Research Directory
Browse clinical research sites, groups, and studies.
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
Sponsor: AstraZeneca
Summary
The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.
Official title: A Phase I, Open-Label, Multi-centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
58
Start Date
2007-03-08
Completion Date
2025-12-31
Last Updated
2025-11-13
Healthy Volunteers
No
Interventions
AZD6244
Participants will receive single oral dose of AZD6244 as described in arm description.
Locations (4)
Research Site
Aurora, Colorado, United States
Research Site
Nijmegen, Netherlands
Research Site
Utrecht, Netherlands
Research Site
Sutton, United Kingdom